In August 2019, fedratinib (INREBIC) received first approval by FDA for the treatment of adults with primary or secondary myelofibrosis. It is an orally bioavailable ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3, with antineoplastic activity. Fedratinib contains pyrimidin moiety in its backbone. We have made a set of Building Blocks, which contain this heterocycle – perfect start for your research!